Alexander R. Gottschalk, MD, PhD

University of Chicago, Chicago, IL, B.A., 1988, Chemistry
University of Chicago, Chicago, IL, Ph.D., 1994, Pathology
University of Chicago, Chicago, IL, M.D., 1996, Medicine
Kaiser Permanente Medical Center, 1996-1997, Internship Medicine
University of California, San Francisco, 1997-2001, Resident Radiation Oncology

• 2001-2008
  Assistant Professor, Department of Radiation Oncology, University of California, San Francisco
• 2007-2008
  Interim Director, CyberKnife Radiosurgery Program, Department of Radiation Oncology, University of California, San Francisco
• 2008-present
  Associate Professor, Department of Radiation Oncology, University of California, San Francisco
• 2008-present
  Director, CyberKnife Radiosurgery Program, Department of Radiation Oncology, University of California, San Francisco

• 1988-96
  NIH Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
• 1998-99
  NIH National Research Service Award, Department of Radiation Oncology, University of California San Francisco
• 2000
  RSNA Research and Education Foundation Roentgen Resident/Fellow Research Award
• 2001-02
  Clinical Investigator Research Program Recipient, University of California San Francisco
• 2002
  Invited speaker at the Radiation Oncology Young Investigator's Symposium, Bethesda, MD,
• 2002-03
  UCSF Prostate Cancer SPORE Developmental Research Program Award
• 2003-05
  RSNA Research Scholar Award
• 2003-05
  American Society of Therapeutic Radiation and Oncology Junior Faculty Award

• Gottschalk AR, Joseph LJ, Quintáns J. Differential induction of Egr-1 expression in WEHI- 231 sublines does not correlate with apoptosis. European Journal of Immunology 23(8):2011-2015, 1993.
• Gottschalk AR, McShan CL, Merino R, Nuñez G, Quintáns J. Physiological cell death in B lymphocytes: I. Differential susceptibility of WEHI-231 sublines to anti-Ig induced physiological cell death and lack of correlation with bcl-2 expression. International Immunology 6(1):121-130, 1994.
• Gottschalk AR, Joseph LJ, Quintáns J. Fc!RII cross-linking inhibits anti-Ig-induced egr-1 and egr-2 expression in BCL1. Journal of Immunology 152(5):2115-2122, 1994.
• Gottschalk AR, Boise LH, Thompson CB, Quintáns J. Identification of immunosuppressantinduced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proceedings of the National Academy of Sciences of the United States of America 91(15):7350-7354, 1994.
• Quintáns J, Kilkus J, McShan CL, Gottschalk AR, Dawson G. Ceramide mediates the apoptotic response of WEHI 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochemical and Biophysical Research Communications 202(2):710-714, 1994.
• Quintáns J., Bonn GA, McShan CL, Gottschalk AR. Studies on the induction of apoptosis in WEHI 231 cells by pharmacological agents and lipid mediators. Sphingosine and ceramide induce apoptosis in WEHI 231. Cell Death and Differentiation 1: 93-99, 1994.
• Quintáns J, and Gottschalk AR. Life and death in lymphocytes: the ceramide connection. The Immunologist 2(6):185-189, 1994.
• Gottschalk AR, McShan CL, Kilkus J, Dawson G, Quintáns J. Resistance to anti-IgMinduced apoptosis in a WEHI-231 subline is due to insufficient production of ceramide. European Journal of Immunology 25(4):1032-1038, 1995.
• Choi MSK, Boise LH, Gottschalk AR, Quintáns J, Thompson CB, Klaus GGB. The role of bcl-xL in CD40-mediated rescue from anti-u-induced apoptosis in WEHI-231 B lymphoma cells. European Journal of Immunology 25(5):1352-1357, 1995.
• Gottschalk AR, and Quintáns J. Apoptosis in B lymphocytes: the WEHI-231 perspective. Immunology and Cell Biology 73(1): 8-16, 1995.
• Boise LH, Gottschalk AR, Quintáns J, Thompson CB. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Current Topics in Microbiology and Immunology 200: 107-121, 1995.
• Gottschalk AR, Boise LH, Oltvai ZN, Accavitti MA, Korsmeyer SJ, Quintáns J, Thompson CB. The ability of Bcl-xL and Bcl-2 to prevent apoptosis can be differentially regulated. Cell Death and Differentiation. 3:113-118, 1996.
• Wiesner DA, Kilkus JP, Gottschalk AR, Quintáns J, Dawson G. Anti-immunoglobulininduced apoptosis in WEHI 231 cells involves the slow formation of ceramide from sphingomyelin and is blocked by bcl-xL. Journal of Biological Chemistry 272(15):9868-9876, 1997.
• Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and Development 14(4):391-396, 2000.
• Gottschalk AR, Basila D, Wong M, Dean N, Brandts CH, Stokoe D, Haas-Kogan DA. p27kip1 is Required for PTEN-induced G1 arrest. Cancer Research 61(5): 2105-2110, 2001.
• Ermoian RS, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, Nicholas MK, Stokoe D, Haas-Kogan DA. Components of the PI3-kinase Signaling Pathway are Associated with Glioma Histology and Patient Survival. Clinical Cancer Research 8: 1100- 1106, 2002.
• Langen, KM, Pouliot, J, Anezinos, C, Aubin, M, Gottschalk, AR, Hsu, IC, Lowther, D, Liu, YM, Shinohara, K, Verhey, LJ, Weinberg, V and Roach, M. Evaluation of ultrasound-based prostate localization for image guided radiation therapy. International Journal of Radiation Oncology* Biology * Physics 57: 635-644, 2003.
• Gottschalk AR and Roach M. The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomized trials. British Journal of Cancer 90(5): 950-4, 2004.
• Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper R, Stokoe D, Haas-Kogan DA. PKB/Akt meditates radiosensitization by the signaling inhibitor LY294002 in human gliomas. Journal of Neuro-Oncology 71(3): 215-22, 2005.
• Gottschalk AR, A. Doan A, Nakamura JL, D. A. Haas-Kogan DA and D. Stokoe D. Inhibition of phosphatidylinositol-3-kinase causes cell death through a PKB dependent mechanism and growth arrest through a PKB independent mechanism. International Journal of Radiation Oncology* Biology * Physics 61 (4): 1183-1188, 2005.
• Master V, Gottschalk AR, Kane C and Carroll PR. Management of patients with isolated recurrence following radical nephrectomy. Journal of Urology 174: 473-477, 2005.
• Hsu IC, Cabrera AR, Weinberg V, Speight J, Gottschalk AR, Shinohara K. Combined Modality Treatment with High Dose Rate Brachytherapy Boost for Locally Advanced Prostate Cancer. Brachytherapy 4: 202-206, 2005.
• Gottschalk AR, A. Doan A, Nakamura JL, D. A. Haas-Kogan DA and D. Stokoe D. Inhibition of phosphotidylinositol-3-kinase causes increased sensitivity to radiation through a PKB dependent mechanism. International Journal of Radiation Oncology*Biology*Physics 63(4):1221-7, 2005.
• Tran QNH, Kim AC, Gottschalk AR, Wara WM, Phillips TL, O'Donnell RJ, James O. Johnston JO, Weinberg V, and Haas-Kogan DA. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma 2006: 1-5, 2006.
• Schiffner D, Gottschalk AR, Lometti M, Aubin M, Pouliot J, Speight J, His IC, Siniohara K and Roach M. Daily Electronic Portal Imaging of Implanted Gold Seed Fiducials in Patients Undergoing Salvage Radiotherapy After Radical Prostatectomy. International Journal of Radiation Oncology*Biology*Physics 67(2): 610-619, 2007.
• Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M, and Hsu IC. High Dose Rate (HDR) Brachytherapy Salvage for Local Prostate Recurrence After Radiotherapy: The UCSF Experience. International Journal of Radiation Oncology*Biology*Physics 67(4): 1106-1112, 2007.
• Morin O, Gillis A, Descovich M, Chen J, Aubin M, Aubry JF, Chen H, Gottschalk AR, Xia P and Pouliot J. Patient dose considerations for megavoltage Cone-Beam CT Imaging. Medical Physics 34(5): 1819-27, 2007.
• Chan L, Xia P, Gottschalk AR, Akazawa M, Scala M, Pickett B, Hsu IC, Speight J, and Roach M. Proposed rectal dose constraints for patients undergoing definitive whole-pelvis radiotherapy for clinically localized prostate cancer. PMID 18342454 International Journal of Radiation Oncology*Biology*Physics 72(1):69-77, 2008.
• Hossain S, Xia P, Chuang C, Verhey L, Gottschalk AR, Mu G, and Ma L. Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. PMID 18841856 Medical Physics 35: 4041-4048, 2008.
• Aubry JF, Cheung J, Morin O, Gottschalk A, Beaulieu L, Pouliot J. Correction of megavoltage cone-beam CT images of the pelvic region based on phantom measurements for dose calculation purposes. PMID 19223832 Journal of Applied Clinical Medical Physics 10(1):2852, 2009.
• Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, and Shinohara K. Salvage permanent perineal radioactive seed implantation for the treatment of localized prostate adenocarcinoma recurrent after external beam radiation. PMID: 19245439 British Journal of Urology Int. 104(5):600, 2009.
• Cheung J, Aubry JF, Yom S, Gottschalk AR, Celi JC and Pouliot J. Dose recalculation and the dose-guided radiation therapy (DGRT) process using megavoltage cone-beam CT. PMID 19345518 International Journal of Radiation Oncology*Biology*Physics 74:583-92, 2009
• Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, McLaughlin Roach M 3rd, Shinohara K. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. PMID 19428310. Brachytherapy 8(4): 339, 2009.
• Ma L, Sahgal A, Hossain S, Chuang C, Descovich M, Huang K, Gottschalk A and Larseon DA. Nonrandom intrafraction target motion and general strategy for correction of spine stereotactic body radiotherapy. PMID 19647951 International Journal of Radiation Oncology*Biology*Physics 75(4):1261, 2009.
• Jabbari S, Weinberg VV, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, and Roach M. Equivalent Biochemical Control and Improved PSA Nadir Following Permanent Prostate Seed Implant Brachytherapy (PPI) Versus High- Dose Three Dimensional Conformal Radiotherapy (3DCRT) and High-Dose Conformal Proton Beam Radiotherapy Boost (CPBRTB). PMID 19409729. International Journal of Radiation Oncology*Biology*Physics 76(1):36, 2010.
• Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M 3rd and Ma L. Dose Gradient near Target and Normal Structure Interface for Non-isocentric CyberKnife and Isocentric Intensity-modulated Body Radiotherapy of Prostate Cancer. In Press. International Journal of Radiation Oncology*Biology*Physics PMID: 20133073. Feb 2, 2010.